Items tagged with HIV coinfection
TB deaths among people living with HIV are declining globally, but worrying gaps in TB care persist (post)
Globally, the number of people living with HIV who died from tuberculosis (TB), a curable and preventable disease, has fallen from almost 600 000 deaths in 2010 to just over 200 000 in 2019, a fall of 63%. In 2016, a global target was set by the United Nations to reduce TB deaths among people living with HIV by 75% between 2010 and 2020. Nine countries (Djibouti, Eritrea, Ethiopia, India, Malawi, South Africa, Sudan, Thailand and Togo) achieved or exceeded the global target by the end of 2019, one year ahead of schedule.
A blood test to find those at high risk of TB in people living with HIV (post)
The Lancet Global Health journal reports the findings of a study of a host blood test that can find those at high risk of tuberculosis in people living with HIV. The blood mRNA biomarker differentiated between people living with HIV who had active tuberculosis from those without TB, and predicted which individuals would develop TB within 15 months.
High-level side event: Ending TB deaths among people with HIV (post)
The World Health Organization will host a special high-level event on the side-lines of the United Nations High-Level Meeting on HIV/AIDS on 7 June 2021.
High-level side event: Ending TB deaths among people with HIV - recording now available online (post)
On 7 June 2021, the World Health Organization hosted a special high-level event on the side-lines of the United Nations High-Level Meeting on HIV/AIDS.
Ending HIV in children is way off target: where to focus action now (post)
World leaders have recently, under the auspices of the United Nations, renewed their commitment to ending AIDS. The new phase offers much needed hope for the future, provided the commitments made are fulfilled.
HIV and TB co-infection skews SARS-CoV-2 T cell response, study finds (post)
A study led by the University of Cape Town has provided new information on the relationship between SARS-CoV-2–specific CD4 response to COVID-19 severity and impact of HIV and TB co-infection.
Here’s how we can move closer to a world without TB and HIV (post)
Before the world was hit by the COVID-19 pandemic, humanity’s deadliest infectious disease was a different respiratory illness, one that we have lived with for millennia: tuberculosis (TB). Vaccines developed and rolled out in record time are already driving a reduction in deaths due to COVID-19. Meanwhile, the outlook for TB remains dark: 4,000 people continue to die of the disease every day, including 700 children. And that curve isn’t budging. Good news in the world of TB has been in short supply this year. In fact, recent research has shown that the countries that bear the biggest TB burdens saw a drastic decrease in TB diagnosis and treatment after COVID-19 hit in late 2019. In just 18 months, the Covid pandemic and the measures taken to address it erased some 12 years of significant and measurable progress against TB. This is bad news for us all.
NIH awards more than $20 million to international HIV database centers (post)
The National Institutes of Health (NIH) has renewed grants to seven regional centers that compose the International epidemiology Databases to Evaluate AIDS (IeDEA), awarding $20.8 million in first-year funding. The 15-year-old IeDEA program efficiently advances knowledge about HIV by pooling and analyzing de-identified health data from more than two million people with HIV on five continents to answer research questions that individual studies cannot address. The grants are expected to last five years and to total an estimated $100 million.
HIV infection may be driving drug resistance in TB (post)
Results published recently in The Lancet Microbe detail analysis of 10 years’ health data, showing a relationship between HIV infection and acquisition of rifampicin resistance by tuberculosis (TB). Rifampicin is an important first‑line anti‑TB medication.
Comparison of 3 preventive TB therapies in patients with HIV infection (post)
Among individuals with HIV infection currently taking antiretroviral therapy (ART), self-administered preventive tuberculosis (TB) therapy with a 3-month course of rifapentine and isoniazid was found to be associated with a significantly increased rate of treatment completion compared with a 6-month course of isoniazid alone, according to results of a study published in Annals of Internal Medicine.
Page 37 of 52 · Total posts: 0
←First 36 37 38 Last→